TABLE 1.
Neutralization of primary HIV-2 isolates by antiserum from mice immunized with envelope proteins derived from HIV-2ALI
| Primary virus isolate | Coreceptor use | V3 net charge (no. of amino acids) | Evolutionary distance from HIV-2ALIa | NAb titer elicited in mice inoculated with different immunogensb |
||||
|---|---|---|---|---|---|---|---|---|
| rVV/ALIM2 | gp125t | rVV/ALIM2 + gp125t | rpC2-C3 | rVV/ALIM2 + rpC2-C3 | ||||
| PTHCC19.03 | R5 | 7 (34) | 0.1521 | 40 | <40 | 1,280 | <40 | 1,280 |
| PTHCC6.03 | R5 | 7 (34) | 0.1582 | 40 | <40 | 160 | <40 | 10,240 |
| PTHCC7.03 | R5 | 7 (34) | 0.1760 | 160 | <40 | 1,280 | <40 | 5,120 |
| PTHCC12.03 | R5 | 7 (34) | 0.1821 | 40 | <40 | 80 | <40 | 5,120 |
| PTHCC2.03 | R5 | 7 (34) | 0.2146 | 40 | <40 | 160 | <40 | 1,280 |
| PTHCC17.03 | R5 | 7 (34) | 0.2323 | 40 | <40 | 320 | <40 | 1,280 |
| PTHSM9.03 | X4 | 9 (35) | 0.2301 | <40c | <40 | <40 | <40 | <40 |
| PTHSM10.03 | X4 | 9 (35) | 0.2214 | <40 | <40 | <40 | <40 | <40 |
| PTHCC20.03 | X4 | 11 (37) | 0.2187 | <40 | <40 | <40 | <40 | <40 |
a
That is, the number of nucleotide substitutions per site in C2, V3, and C3 under maximum likelihood.
b
Endpoint titters measured in TZM-bl cells are the reciprocal serum dilutions that reduced virus replication by >50%.
c
Non-neutralizable at 1/40 serum dilution.